...
首页> 外文期刊>RSC Advances >Seeking potent anti-tubercular agents: design and synthesis of substituted-N-(6-(4-(pyrazine-2-carbonyl)piperazine/homopiperazine-1-yl)pyridin-3-yl)benzamide derivatives as anti-tubercular agents
【24h】

Seeking potent anti-tubercular agents: design and synthesis of substituted-N-(6-(4-(pyrazine-2-carbonyl)piperazine/homopiperazine-1-yl)pyridin-3-yl)benzamide derivatives as anti-tubercular agents

机译:寻求有效的抗结核剂:设计和合成取代 - N-(6-(4-(吡嗪-2-羰基)哌嗪/衍生物-1-基)吡啶-3-基)苯胺衍生物作为抗结核剂

获取原文
获取原文并翻译 | 示例
           

摘要

Pyrazinamide is an important first-line drug used in shortening TB therapy. In our current work, a series of novel substituted-N-(6-(4-(pyrazine-2-carbonyl)piperazine/homopiperazine-1-yl)pyridin-3-yl)benzamide derivatives were designed, synthesized, and evaluated for their anti-tubercular activity against Mycobacterium tuberculosis H37Ra. Among the tested compounds, five compounds (6a, 6e, 6h, 6j and 6k) from Series-I and one compound (7e) from Series-II exhibited significant activity against Mycobacterium tuberculosis H37Ra with 50% inhibitory concentrations (IC50) ranging from 1.35 to 2.18 mu M. To evaluate the efficacy of these compounds, we examined their IC90 values. Five of the most active compounds were found to be more active with IC(90)s ranging from 3.73 to 4.00 mu M and one compound (6e) showed an IC90 of 40.32 mu M. Moreover, single crystals were developed for 6d, 6f and 6n. In addition, most active compounds were evaluated for their cytotoxicity on HEK-293 (human embryonic kidney) cells. Our results indicate that the compounds are nontoxic to human cells. The molecular interactions of the derivatised conjugates in docking studies reveal their suitability for further development.
机译:吡嗪酰胺是一种重要的第一线用于缩短结核病疗法的一线药物。在我们目前的工作中,设计了一系列新的取代 - N-(6-(4-(吡嗪-2-羰基)哌嗪/丙嗪-1-基)吡啶-3-基)苯胺衍生物,合成,并评价对抗结核分枝杆菌H37RA的抗结核活动。在测试的化合物中,来自Series-II系列和一种化合物(7e)的五种化合物(6a,6e,6h,6j和6k)表现出针对分枝杆菌的分枝杆菌H37ra具有显着的活性,具有50%的抑制浓度(IC50),范围为1.35为了评估这些化合物的功效,我们检查了它们的IC90值。发现五种最活跃的化合物与IC(90)的范围从3.73〜4.00 mu m的Ic(90),并且一种化合物(6e)显示IC90为40.32μm。此外,为6d,6f和6f开发单晶6N。此外,在HEK-293(人胚胎肾)细胞上对其细胞毒性评估大多数活性化合物。我们的结果表明该化合物对人细胞无毒。对接研究中衍生的缀合物的分子相互作用揭示了他们对进一步发展的适用性。

著录项

  • 来源
    《RSC Advances》 |2020年第21期|共17页
  • 作者单位

    Birla Inst Technol &

    Sci Dept Chem Hyderabad Campus Hyderabad 500078 Telangana India;

    Birla Inst Technol &

    Sci Dept Chem Hyderabad Campus Hyderabad 500078 Telangana India;

    Birla Inst Technol &

    Sci Dept Chem Hyderabad Campus Hyderabad 500078 Telangana India;

    Univ Ghent Fac Biosci Engn Dept Green Chem &

    Technol Coupure Links 653 B-9000 Ghent Belgium;

    Univ Ghent Fac Biosci Engn Dept Green Chem &

    Technol Coupure Links 653 B-9000 Ghent Belgium;

    Univ Ghent Fac Biosci Engn Dept Green Chem &

    Technol Coupure Links 653 B-9000 Ghent Belgium;

    Birla Inst Technol &

    Sci Dept Pharm Hyderabad Campus Hyderabad 500078 Telangana India;

    Birla Inst Technol &

    Sci Dept Chem Hyderabad Campus Hyderabad 500078 Telangana India;

    Birla Inst Technol &

    Sci Dept Pharm Med Chem Res Lab Pilani 333031 Rajasthan India;

    Birla Inst Technol &

    Sci Dept Chem Hyderabad Campus Hyderabad 500078 Telangana India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号